Abstracts

ACTIVATING PKC-? INDUCES HIV EXPRESSION WITH IMPROVED TOLERABILITY

Activation of latent HIV could increase elimination of infected cells by therapeutics that directly target infected cells or stimulate antiviral immunity, potentially leading to long-term remission or cure. Protein kinase C (PKC) agonists are highly effective at activating latent HIV in vitro. We previously found that platelet activation is associated with toxicity of novel PKC…

VENETOCLAX SIGNIFICANTLY REDUCES HIV VIRAL LOAD IN VIVO AND IN VITRO

The BCL-2 pro-survival protein has been implicated in HIV persistence, and we have previously demonstrated that the clinically used BCL-2 inhibitor Venetoclax augments HIV induced killing of the reactivating cell, in vitro. It is unknown whether Venetoclax impacts HIV dynamics in vivo. We hypothesized that Venetoclax would reduce HIV replication in a murine model of…

AUTOLOGOUS VIRUS-NEUTRALIZING ANTIBODIES DELAY VIRUS REBOUND IN INFANT SHIV MODEL

Early ART improves disease outcomes in infected children but does not eliminate latent HIV reservoirs. Studies in a small subset of perinatally infected children who developed HIV-specific antibody responses and remained virus free when ART was interrupted, suggested that autologous antibody responses maybe important for sustained viral control and lack of virus rebound. However, kinetics…

VIRUS REMISSION WITH AN OPTIMIZED EARLY ART REGIMEN IN MACAQUES

Early initiation of antiretroviral therapy (ART) does not cure HIV in humans or SIV in macaques due to rapid viral reservoir establishment. Here, we investigated in macaques if a novel ART regimen, designed to have robust penetration in virus reservoir sites, can result in virus remission after treatment cessation. The ART regimen included daily tenofovir…

EFFECTS OF PD-1 BLOCKADE ON HIV RESERVOIRS IN BLOOD DURING ART

Blockade of the programmed cell death protein-1 (PD-1) pathway can reverse HIV latency, can potentiate virus-specific CD8 T cell responses, and has been associated with favorable outcome in some cases of central nervous system (CNS) infection. The effects of PD-1 blockade on CNS reservoirs for HIV are under study in clinical trial NCT03239899. We evaluated…